Together Pharma Ltd
TGPHF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.01 | 0.00 | -0.02 |
| FCF Yield | 48.82% | -55.56% | -117.21% | -138.59% |
| EV / EBITDA | 2.89 | -5.48 | -15.78 | 3.33 |
| Quality | ||||
| ROIC | -33.96% | -18.29% | -8.24% | 15.29% |
| Gross Margin | 38.04% | -18.85% | -18.07% | -52.03% |
| Cash Conversion Ratio | -3.44 | 0.41 | 1.35 | -1.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 96.33% | 40.65% | – | – |
| Free Cash Flow Growth | 199.28% | 30.28% | 13.99% | -57.56% |
| Safety | ||||
| Net Debt / EBITDA | 1.85 | -3.72 | -12.98 | 2.50 |
| Interest Coverage | 0.00 | -1.16 | -0.77 | 1.40 |
| Efficiency | ||||
| Inventory Turnover | 1.02 | 0.83 | 0.31 | 0.46 |
| Cash Conversion Cycle | 319.28 | 444.10 | 1,064.23 | 673.41 |